News

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd),…
Read More...

Kazia Therapeutics Limited an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of…
Read More...

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics Orion Corporation (“Orion”) and Invenra…
Read More...

ImmunityBio, Inc. announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, Ltd.), a global oncology company, to conduct a…
Read More...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced that the European Commission has authorised…
Read More...

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for once every four weeks…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application…
Read More...

Pfizer Inc.announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil,…
Read More...

AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, announced a C$820 million (US$570m) investment in Canada, creating more than 700 high-skilled…
Read More...

AbbVie and Neomorph, Inc. announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.…
Read More...

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated new Drug Application…
Read More...

Tevogen Bio Holdings Inc.(opens in a new window) a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious…
Read More...

Zai Lab Limited announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug…
Read More...

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived…
Read More...

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has been awarded a share of the £3…
Read More...

Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO (esketamine) CIII nasal spray, making…
Read More...

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its…
Read More...

Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DYNE-101 for the treatment of myotonic dystrophy type 1 (DM1).…
Read More...

Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, announced a strategic collaboration with Galapagos NV (Euronext &…
Read More...

Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody Drug Conjugates (ADCs) with breakthrough potential, proudly…
Read More...